The 10-Year Health Plan marks a significant step forward in building an NHS that is faster, fairer and fit for the future. At NICE, we’re ready to deliver - using our expanded remit to accelerate ...

The new approach will ensure that high-impact devices, diagnostics and digital tools recommended by NICE, that meet the most urgent needs, are nationally reimbursed and made available across the NHS - ...

NICE-recommended digital therapies for depression and anxiety could free up thousands of NHS therapist hours NHS Talking Therapies for anxiety and depression services saw record referrals in 2023/24.

In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented ...

New guideline will help cut falls and related hospital admissions for older and at-risk people Personalised assessments that consider factors including the hazards in a person’s home, and their ...

Suggested remit: To appraise the clinical and cost effectiveness of nemolizumab within its marketing authorisation for treating moderate to severe atopic dermatitis in people aged 12 and over.

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on nemolizumab for treating moderate to severe atopic dermatitis in people 12 years ...

The meeting will take place as a meeting via Zoom, a secure web conferencing tool. This meeting will run from 9:00am to 5:00pm, although timings may be subject to change. You will receive your ...

Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults. Last reviewed: 25 June 2025 Next review: This guidance will be reviewed if ...

Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies. Last reviewed: 24 June 2025 Next review: ...

Hybrid closed loop (HCL) systems are recommended as an option for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling ...

Our position on the use of AI in evidence generation and reporting There are several potential benefits to using AI methods in health technology assessment (HTA). These must be balanced against ...